Although he was on medication, an 80-year-old patient was being hospitalized every 2 to 3 months for congestive heart failure. ... Only once he began seeing a prevention nurse in a special heart failure clinic every week did his condition improve.
https://acpinternist.org/weekly/archives/2014/09/09/2.htm. A new drug that combines a neprilysin inhibitor and an angiotensin-receptor blocker (ARB) reduced deaths and hospitalization for heart failure ... A new drug that combines a neprilysin inhibitor
https://acpinternist.org/weekly/archives/2011/04/26/5.htm. Patients with severe acute heart failure appear to benefit from beta-blocker therapy after hospital discharge, a new study reports. ... Patients with severe acute heart failure appear to benefit
Expanded indication for 2 cardiac resynchronization pacemakers and 8 cardiac resynchronization defibrillators by Medtronic to treat patients with atrioventricular (AV) block and less severe heart failure. ... The FDA previously approved these devices for
Darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild to moderate anemia, a study found. ... Primary clinical outcomes were death from any cause or first hospitalization for worsening heart failure.
systolic heart failure and were in stable condition (New York Heart Association class II and III, ejection fraction 35%). ... Sixty-four percent had class II heart failure and 36% had class III/IV heart failure.
Updated heart failure performance measures, released last week by three major medical groups, include expanded use for beta-blockers in the inpatient setting. ... Changes to outpatient measures include:. LVEF assessment. The description was modified
In August, the entire class of thiazolidinediones added boxed warnings saying the drugs may cause or worsen heart failure. ... Medical professionals should monitor patients for 30 minutes after infusion, and shouldn't use the drugs in patients with
Researchers analyzed data from 1,458 heart failure patients in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. ... Still, the results should help physicians adhere to clinical practice guidelines that
https://acpinternist.org/archives/2016/02/editors.htm. This issue covers topics such as retail clinics, management of heart failure, and optimizing human papillomavirus vaccination. ... Managing heart failure is a complicated clinical area that is only